Rocket Pharmaceuticals (RCKT) Stock Target Reduced Following Q3 2025 Update on Cash Position
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the stocks that will double in 2026.
Rocket Pharmaceuticals Inc. (RCKT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Maverick Capital Lee Ainslie | 8,468,344 | $27,606,801 | +2% | 0.37% |
| 2. | BioImpact Capital Mpm Capital | 3,903,381 | $12,725,022 | +1% | 2.08% |
| 3. | Suvretta Capital Management Aaron Cowen | 3,843,333 | $12,529,266 | -8% | 0.32% |
| 4. | Millennium Management Israel Englander | 3,570,391 | $11,639,475 | +53% | 0% |
| 5. | Newtyn Management Noah Levy And Eugene Dozortsev | 2,502,863 | $8,159,333 | +26% | 1% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.44 | 10,000 | $34,400.00 | 50,000 | 2026-01-02 | Filing | |
| $3.41 | 10,000 | $34,100.00 | 40,000 | 2025-08-27 | Filing | |
| $5.08 | 20,000 | $101,600.00 | 792,680 | 2025-04-10 | Filing | |
| $4.70 | 21,099 | $99,165.30 | 26,774 | 2025-04-09 | Filing | |
| $14.75 | 1,355,932 | $19,999,997.00 | 17,628,567 | 2022-10-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.98 | 2,545 | $7,591.74 | 299,064 | 2025-11-18 | Filing | |
| $2.98 | 6,276 | $18,721.31 | 778,296 | 2025-11-18 | Filing | |
| $2.98 | 1,086 | $3,239.54 | 65,920 | 2025-11-18 | Filing | |
| $2.98 | 1,646 | $4,910.02 | 383,816 | 2025-11-18 | Filing | |
| $3.98 | 558 | $2,218.05 | 67,006 | 2025-10-14 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 309,247 | $1,085,457 | 0.04% | |
| 2. | 32,515 | $114,128 | 0% | |
| 3. | 20,000 | $70,200 | 0% | |
| 4. | 18,230 | $64,533 | 0% | |
| 5. | 13,492 | $47,357 | 0% |
News See All
20 Stocks That Will Double in 2026
On December 8, Kevin Mahn of Hennion & Walsh appeared on CNBC's 'Closing Bell Overtime' to discuss the potential for another bullish year, but with more volatility.
Is Rocket Pharmaceuticals (RCKT) One of the Best NASDAQ Stocks Under $5 to Buy Now?
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the best NASDAQ stocks under $5 to buy now.
11 Best NASDAQ Stocks Under $5 to Buy Now
On October 9, Scott Ladner, Chief Investment Officer at Horizon Investments, appeared on CNBC to suggest that AI remains the key market driver along with tech.
Jefferies Raises PT on Rocket Pharmaceuticals, Inc. (RCKT) to $3.00; Maintains ‘Hold’ Rating
With significant hedge fund interest and a share price under $10, Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals Reorganizes, Cuts Workforce by 30% to Focus on AAV Cardiovascular Platform
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the most promising penny stocks under $5.
11 Best Single Digit Stocks to Buy According to Hedge Funds
The winning streak of U.S. stocks extended on Wednesday, August 13, 2025, with the S&P 500 and Nasdaq reaching fresh record highs for the second day in a row.
13 Most Promising Penny Stocks Under $5
On August 12, Jill Carey Hall, BofA Securities head of US small and mid-cap strategy, joined 'The Exchange' on CNBC to discuss the outlook for small caps, amidst their underperformance.
Rocket Pharmaceuticals Restructures, Lays Off 30% of Workforce to Focus on Cardiovascular, LAD-I Gene Therapies
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the biotech stocks to buy according to Wall Street analysts.
10 Biotech Stocks to Buy According to Wall Street Analysts
On July 8, Jared Holz, Mizuho, joined 'Closing Bell Overtime' on CNBC to discuss if the biotech sector is ready for a breakout.